clinical trial · NCT03436693
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Diabetic NephropathyCanagliflozinPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
started
Feb 15, 2018
primary completion
Jan 21, 2021
completion
Jan 21, 2021
last updated
Jan 7, 2026
official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol